Welcome to MutualFunds.com. Please help us personalize your experience.
Your personalized experience is almost ready.
Check your email and confirm your subscription to complete your personalized experience.
Thank you for your submission, we hope you enjoy your experience
Shares of Tekmira Pharmaceuticals (TKMR) have been surging as the company is now in clinical trials to create a drug for the virus. The company has been given approval by the FDA to give its TKM-Ebola drug to subjects “with confirmed or suspected Ebola virus infections.”
The recent U.S. case of Ebola in the U.S. also now has pharmaceutical companies racing to create a vaccine for the virus.
The companies involved in the treatment or vaccination of the virus range from small biotech companies to pharma giants like GlaxoSmithKline (GSK).
|Ticker||Mutual Fund||Exposure||% of Shares Owned|
|FBDIX||Franklin Biotechnology Discovery A||Tekmira Pharmaceuticals (TKMR)||3.15%|
|SHSAX||BlackRock Health Sciences Opps Inv A||Tekmira Pharmaceuticals (TKMR)||1.53%|
|FBIOX||Fidelity Select Biotechnology Portfolio||NewLink Genetics Corp (NLNK)||5.93%|
There are several mutual funds that offer specific exposure to these industries including the funds listed above.
Subscribe to receive FREE updates, insigns, and more, straight to your inbox